NMN Human Trials: What the Studies Found

The direct answer

Human trials support one repeatable conclusion: oral NMN can increase blood NAD+ or related NAD measures over several weeks. They do not yet support the broader claim that NMN supplements extend human lifespan, reverse aging, or reliably improve glucose control, body composition, strength, walking performance, or sleep.

The distinction matters because NAD+ is a biomarker, while outcomes such as walking speed, insulin resistance, sleep quality, and adverse events answer different questions. A biomarker can move without producing a meaningful change in how a person feels or functions.

Four useful evidence snapshots

Read the prespecified primary outcome before the secondary findings.

Selected NMN human trials and meta-analyses
Evidence	Participants	Protocol	Main result and limit
Okabe et al., 2022Randomized, double-blind, placebo-controlled	30 healthy adults; 29 completed	250 mg/day for 12 weeks	Whole-blood NAD+ increased; no obvious adverse effects were reported. Small, short trial.
Yi et al., 2023Randomized, multicenter, dose-ranging	80 healthy middle-aged adults	Placebo or 300, 600, or 900 mg/day for 60 days	Blood NAD and six-minute walk distance increased; HOMA-IR did not differ from placebo. Sixty-day follow-up.
Morifuji et al., 2024Randomized, double-blind, placebo-controlled	60 older adults	250 mg/day for 12 weeks	No difference in the primary stepping test; secondary findings included four-meter walk time, blood NAD+, and sleep scores.
Yang et al., 2026Systematic review and meta-analysis	15 trials; 10 contributed to safety analyses	250 to 2,000 mg/day for 14 days to 24 weeks	No clear short-term increase in adverse events or liver enzymes; broad metabolic benefits were not evident. Long-term safety remains unresolved.

Biomarkers are stronger than clinical outcomes

Blood NAD+ is the most consistent trial result. Okabe et al. reported an increase after 250 mg daily for 12 weeks. Yi et al. reported increases at 300 mg, 600 mg, and 900 mg daily over 60 days. Morifuji et al. also reported higher blood NAD+ and related metabolites after 250 mg daily for 12 weeks.

Physical-function results depend on the test. Yi et al. reported a greater increase in six-minute walking distance than placebo. Morifuji et al. found no significant difference in its primary stepping-test outcome, but reported a shorter four-meter walk time as a secondary outcome. Those findings cannot be collapsed into the claim that NMN reliably improves walking performance.

Metabolic claims are less persuasive. The Yi trial found no significant HOMA-IR difference from placebo. A 2025 meta-analysis of 12 studies and 513 participants found that blood NAD increased, while most clinically relevant glucose and lipid outcomes did not differ significantly from control groups. That review rated seven studies as having some risk-of-bias concerns and five as high risk.

Dose and duration are study conditions, not instructions

The doses in the selected trials range from 250 mg to 900 mg daily, and the 2026 meta-analysis included studies up to 2,000 mg daily. These numbers describe experimental protocols. They are not a dose recommendation and do not show that a higher amount works better for a particular person.

Trial products also cannot be treated as interchangeable retail products. A study may use a defined test material with its own purity, manufacturing, storage, and protocol. A store-bought bottle needs separate evidence that its finished product contains the labeled amount and meets its specifications.

What the safety data can support

Short-term tolerability has been generally favorable within the populations, doses, and durations studied. Okabe et al. reported no obvious adverse effects or physiological and laboratory abnormalities over 12 weeks. Yi et al. reported no safety issue across the 60-day study. Morifuji et al. reported no adverse effect related to the test substance over 12 weeks.

The 2026 meta-analysis included 15 trials, with doses from 250 mg to 2,000 mg daily and durations from 14 days to 24 weeks. It found no clear increase in overall adverse events, serious adverse events, withdrawal-related adverse events, or ALT and AST. The same review said larger and longer trials are needed to confirm long-term safety.

Short studies in selected adults cannot resolve years of use, uncommon adverse events, pregnancy, breastfeeding, pediatric use, or all medication and disease combinations. Absence of a signal in a small trial is not proof that every use is risk-free.

Funding and conflicts belong beside the result

Commercial involvement does not automatically invalidate a study, but it changes how confidently a result should be generalized. Four authors in the Okabe trial were employees of the company that prepared the NMN and placebo. The Yi paper lists authors employed by Abinopharm and ABA Chemicals. Three authors in the Morifuji paper were employees of Meiji Holdings.

Study size, duration, endpoint selection, registration, analysis, and replication still matter. Funding and employment should be read with those design features, not used as a substitute for reviewing them.

What the evidence supports today

Supported: oral NMN can raise blood NAD measures over several weeks in studied adults.
Not established: a reliable improvement across metabolic or physical outcomes.
Not established: prevention or treatment of disease.
Not established: slower biological aging or longer human lifespan.
Still limited: safety beyond the short durations studied.
Separate question: whether a retail bottle matches its label and test records.

Start with what NMN supplements are, then use the NMN certificate of analysis guide to evaluate product records. Our five-product comparison does not award clinical benefits based on a label dose alone.